Germany
· Delayed Price · Currency is EUR BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of EUR 20.76 billion. The enterprise value is 7.54 billion.
| Market Cap | 20.76B |
| Enterprise Value | 7.54B |
Important Dates
The last earnings date was Monday, May 5, 2025.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.51% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 93.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.56 |
| PB Ratio | 1.10 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.84 |
| EV / Sales | 2.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.15 |
Financial Position
The company has a current ratio of 10.18, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.18 |
| Quick Ratio | 9.86 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.55 |
| Interest Coverage | -80.81 |
Financial Efficiency
Return on equity (ROE) is -3.94% and return on invested capital (ROIC) is -4.05%.
| Return on Equity (ROE) | -3.94% |
| Return on Assets (ROA) | -3.67% |
| Return on Invested Capital (ROIC) | -4.05% |
| Return on Capital Employed (ROCE) | -6.50% |
| Revenue Per Employee | 405,538 |
| Profits Per Employee | -113,113 |
| Employee Count | 6,772 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 1.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.57% in the last 52 weeks. The beta is 1.36, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -4.57% |
| 50-Day Moving Average | 87.71 |
| 200-Day Moving Average | 99.72 |
| Relative Strength Index (RSI) | 48.68 |
| Average Volume (20 Days) | 2,186 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.13 |
Income Statement
In the last 12 months, BioNTech SE had revenue of EUR 2.75 billion and -766.00 million in losses. Loss per share was -3.19.
| Revenue | 2.75B |
| Gross Profit | 2.18B |
| Operating Income | -1.28B |
| Pretax Income | -791.30M |
| Net Income | -766.00M |
| EBITDA | -1.02B |
| EBIT | -1.28B |
| Loss Per Share | -3.19 |
Balance Sheet
The company has 14.11 billion in cash and 293.00 million in debt, giving a net cash position of 13.82 billion.
| Cash & Cash Equivalents | 14.11B |
| Total Debt | 293.00M |
| Net Cash | 13.82B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 18.93B |
| Book Value Per Share | 78.73 |
| Working Capital | 14.09B |
Cash Flow
In the last 12 months, operating cash flow was -255.70 million and capital expenditures -276.90 million, giving a free cash flow of -532.60 million.
| Operating Cash Flow | -255.70M |
| Capital Expenditures | -276.90M |
| Free Cash Flow | -532.60M |
| FCF Per Share | n/a |
Margins
Gross margin is 79.39%, with operating and profit margins of -46.49% and -27.89%.
| Gross Margin | 79.39% |
| Operating Margin | -46.49% |
| Pretax Margin | -28.81% |
| Profit Margin | -27.89% |
| EBITDA Margin | -37.14% |
| EBIT Margin | -46.49% |
| FCF Margin | n/a |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.51% |
| Shareholder Yield | n/a |
| Earnings Yield | -3.69% |
| FCF Yield | -2.57% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 8.04.
| Altman Z-Score | 8.04 |
| Piotroski F-Score | n/a |